Singapore markets closed

Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
9.53+1.16 (+13.86%)
As of 10:53AM EDT. Market open.

Aeterna Zentaris Inc.

222 Bay Street
Suite 3000 PO Box 53
Toronto M5K 1E7

Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Klaus Paulini Ph.D.President, CEO & Executive Director370.64kN/AN/A
Mr. Giuliano La FrattaSenior VP of Finance & CFO254.19kN/AN/A
Dr. Michael Teifel Ph.D.Senior VP of Non-Clinical Development & Chief Scientific Officer212.57kN/AN/A
Dr. Nicola Ammer M.D.Chief Medical Officer & Senior VP of Clinical Development202.81kN/AN/A
Dr. Matthias GerlachSenior Vice President Manufacturing & Supply Chain213.43kN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Corporate governance

Aeterna Zentaris Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.